Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 51-75 of 581 citing articles:

Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study
María‐Eugenia Zaballa, Javier Perez‐Saez, Carlos de Mestral, et al.
The Lancet Regional Health - Europe (2022) Vol. 24, pp. 100547-100547
Open Access | Times Cited: 41
COVID-19 Vaccines: Current and Future Perspectives
Luca Soraci, Fabrizia Lattanzio, Giulia Soraci, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 608-608
Open Access | Times Cited: 37
Nanomaterials for mRNA‐based therapeutics: Challenges and opportunities
Defeng Li, Qisong Liu, Meifeng Yang, et al.
Bioengineering & Translational Medicine (2023) Vol. 8, Iss. 3
Open Access | Times Cited: 36
A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
Hassen Mohammed, Dan Duy Pham-Tran, Zi Yi Michelle Yeoh, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 224-224
Open Access | Times Cited: 34
Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain
Leerang Yang, Matthew Van Beek, Zijun Wang, et al.
Cell Reports (2023) Vol. 42, Iss. 4, pp. 112256-112256
Open Access | Times Cited: 34
Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review
Pradipta Paul, Ahmed El-Naas, Omar Hamad, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 34
Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study
Celine Y. Tan, Calvin J. Chiew, Deanette Pang, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 12, pp. 1343-1348
Open Access | Times Cited: 34
An Analysis of COVID-19 Mortality During the Dominancy of Alpha, Delta, and Omicron in the USA
Mohammad Tabatabai, Paul D. Juárez, Patricia Matthews-Juarez, et al.
Journal of Primary Care & Community Health (2023) Vol. 14
Open Access | Times Cited: 32
Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023
Jennifer DeCuir, Diya Surie, Yuwei Zhu, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 17, pp. 463-468
Open Access | Times Cited: 31
Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study
Sho Nakakubo, Naoki Kishida, Kenichi Okuda, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 11, pp. 1244-1256
Open Access | Times Cited: 30
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19
Wesley H. Self, Matthew S. Shotwell, Kevin W. Gibbs, et al.
JAMA (2023) Vol. 329, Iss. 14, pp. 1170-1170
Open Access | Times Cited: 29
Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021–January 2022
Brechje de Gier, Liselotte van Asten, Tjarda M. Boere, et al.
Vaccine (2023) Vol. 41, Iss. 31, pp. 4488-4496
Open Access | Times Cited: 29
Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 29
Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron
Yuchen Wei, Katherine Min Jia, Shi Zhao, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2254777-e2254777
Open Access | Times Cited: 28
Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic
Luis Daniel González-Vázquez, Miguel Arenas
Genes (2023) Vol. 14, Iss. 2, pp. 407-407
Open Access | Times Cited: 27
Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021–August 2022
Noah Kojima, Katherine Adams, Wesley H. Self, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 4, pp. 547-557
Open Access | Times Cited: 26
Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial
Jianchao Xu, Jinzhong Song, Ziyu Xie, et al.
Medicine (2023) Vol. 102, Iss. 51, pp. e36714-e36714
Open Access | Times Cited: 26
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Raju Sunagar, Amit Kumar Singh, Sudeep Kumar
Vaccines (2023) Vol. 11, Iss. 4, pp. 849-849
Open Access | Times Cited: 23
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 23
Differences between the course of SARS-CoV-2 infections in the periods of the Delta and Omicron variants dominance in Poland
Krystyna Dobrowolska, Michał Brzdęk, Dorota Zarębska‐Michaluk, et al.
Polskie Archiwum Medycyny Wewnętrznej (2023)
Open Access | Times Cited: 22
IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System
Vladimir N. Uversky, Elrashdy M. Redwan, William Makis, et al.
(2023)
Open Access | Times Cited: 21
Probable Transmission of SARS-CoV-2 from African Lion to Zoo Employees, Indiana, USA, 2021
Audrey A. Siegrist, Kira L. Richardson, Ria R. Ghai, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 6
Open Access | Times Cited: 21
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
Leora R. Feldstein, Amadea Britton, Lauren Grant, et al.
JAMA (2024) Vol. 331, Iss. 5, pp. 408-408
Open Access | Times Cited: 13
mRNA Vaccine Nanoplatforms and Innate Immunity
Lai Wei, Chunhong Dong, Wandi Zhu, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 120-120
Open Access | Times Cited: 11
Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall–Winter 2022–2023: A Cross-Sectional Retrospective Study
Hagit Kopel, Alina Bogdanov, Jessamine Winer‐Jones, et al.
Diseases (2024) Vol. 12, Iss. 1, pp. 16-16
Open Access | Times Cited: 9

Scroll to top